Hoppa till innehål

News

New Preclinical Findings Identify HVEM as a Promising Target in Aggressive Glioblastoma

Researchers have identified HVEM as a promising therapeutic target in mesenchymal glioblastoma...

Kohei Miyazono new member at the royal Swedish academy of science.

Kohei Miyazono has been elected as a new member to the Academy’s class for medical sciences at the royal ...

US Patent Application IP001 Receives Notice of Allowance

The US patent application IP001 has received an allowance for protection of our novel HVEM antagonistic single domain antibodies.

Almi Invest Invests in Mesenkia Therapeutics

Mesenkia Therapeutics has secured an investment from Almi Invest as part of a SEK 5.6 million financing round. The ...

International Research Collaboration Brings Hope for Glioblastoma Treatment

Mesenkia Therapeutics was founded to advance years of research from scientists at Uppsala University and the University of Tokyo into ...

Contact press@mesenkia.com for interviews, press materials, company information and high-resolution images.

Let's build the future for next generation cancer therapies

Whether you’re an investor looking for first-in-class potential or a partner exploring co-development, we’d be glad to start the conversation.

Partner with us

Cookiesamtycke

På webbplatsen används nödvändiga kakor för att webbplatsen ska fungera på ett bra sätt. Du kan även välja att samtycka till kakor för statistikinsamling.